PREPARING FOR
THE NEW POSSIBLE
November 14 – 15, 2018 • Harvard Medical School, Boston, MA
Schedule
Part I
The Infrastructure for Innovation
“We need to make the transition to a predict, prevent and protect health system.”
Senior Vice President, Global Value, Access and Policy, Amgen
*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***
Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115
SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
SPEAKER | TBD
Government executives have an enormous influence over the direction of health systems and can therefore play a role in developing personalized medicine — but they need to know what works and what doesn’t if their respective efforts to promote personalized medicine are going to succeed. With that in mind, government representatives from around the globe will discuss the competitive advantages various countries have in personalized medicine and explore the common challenges and notable achievements of government initiatives to advance the field during this panel discussion.
MODERATOR | Antonio L. Andreu, M.D., Ph.D., Scientific Director, European Infrastructure for Translational Medicine
Ora Dar, Ph.D., Senior Expert, National Research & Development Projects, Technological Infrastructure Division, Israel Innovation Authority
Tom Fowler, Ph.D., Deputy Chief Scientist, Genomics England
Marc LePage, President, CEO, Genome Canada
Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Ministry of Social Affairs and Health, Finland
Light refreshments provided.
MODERATOR | Susan McClure, Founder, Publisher, Genome magazine
Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation
Artificial intelligence presents new opportunities for researchers to identify how genes, proteins and other biological characteristics contribute to human disease, thereby informing personalized medicine. During this session, a diverse panel will separate knowledge from hype by discussing how artificial intelligence may accelerate drug development, improve clinical decision support, and drive patient outcomes in areas including but not limited to oncology and neurodegenerative diseases.
MODERATOR | William S. Dalton, Ph.D., M.D., Founder, Executive Chairman, M2Gen; Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center
Colin Hill, Chairman, CEO, co-Founder, GNS Healthcare
Thomas J. Miller, Executive Chairman, Atlas5D
Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche
Darrell M. West, Ph.D., Vice President of Governance Studies, Director of the Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution
SPEAKER | David King, J.D., Chairman, CEO, LabCorp
The U.S. Food and Drug Administration and the U.S. Centers for Medicare and Medicaid Services have been working for over a decade to develop regulatory and reimbursement pathways that promote the development of innovative diagnostic tests. Many industry representatives, however, believe the current regulatory and reimbursement landscape limits the field. This panel of business leaders will discuss the extent to which the existing frameworks and proposed policies may help or hinder personalized medicine.
MODERATOR | Joseph V. Ferrara, CEO, Boston Healthcare Associates
Michael Doherty, Senior Vice President, Head of Product Development, Foundation Medicine
Julie Khani, President, American Clinical Laboratory Association
Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health
Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific
Light refreshments provided.
Public and private sector policies related to biomedical research, regulation, and reimbursement will determine whether health systems have the flexibility to leverage real-world evidence and digital health technologies to update personalized care regimens in real time. This panel of experts will discuss their perspectives on policy solutions that will facilitate the use of real-world evidence and digital health technologies for the purposes of treatment development, label expansions, evidence generation, and patient empowerment.
MODERATOR | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition
Jesse Berlin, Sc.D., Vice President and Global Head of Epidemiology, Johnson and Johnson
TBD
TBD
Advancing a medical paradigm that focuses on the unique characteristics of each patient will require, by definition, that patients from diverse backgrounds participate in the medical studies that advance our understanding of disease and have access to personalized care informed by those studies. During this session, three panelists will discuss the effort to ensure that all patient populations benefit equally from personalized medicine.
MODERATOR | Donna R. Cryer, J.D., President, CEO, Global Liver Institute
Vence L. Bonham, J.D., Senior Advisor to the Director on Genomics and Health Disparities, U.S. National Human Genome Research Institute
Alex J. Carlisle, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health
Adolph P. Falcón, Executive Vice President, National Alliance for Hispanic Health
SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health
Avenue of the Arts
465 Huntington Avenue
Boston, MA 02115
Welcome Reception
At the Boston Museum of Fine Arts
November 14, 2018 – 6:15 p.m.
465 Huntington Ave., Boston, MA 02115
Sponsored by
Part II
The Business of Personalization
“The successful implementation of [personalized medicine] will depend on the embrace of [its] principles in the business community.”
Paul C. Cabot Professor of Genetics, Harvard Medical School
*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***
Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115
SPEAKER | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics US Inc.
MODERATOR | Meg Tirrell, Reporter, CNBC
Daniel O’Day, CEO, Roche Pharmaceuticals
The pharmaceutical industry is deeply invested in commercializing personalized therapies that must recoup development costs from smaller patient populations. In that context, this diverse panel will explore the viability of the business model for developing and paying for personalized medicines, tackling issues related to costs, prices, and access.
MODERATOR | Meg Tirrell, Reporter, CNBC
Nick Leschly, CEO, Bluebird Bio
Joshua Ofman, M.D., M.S.H.S., Senior Vice President, Global Value, Access and Policy, Amgen
Michael Sherman, M.D., M.B.A., M.S., Chief Medical Officer, Senior Vice President, Harvard Pilgrim Health Care
INTRODUCTION | Steven D. Averbuch, M.D., Vice President, Head of Precision Medicine, Bristol-Myers Squibb
AWARDEE | Ellen V. Sigal, Ph.D., Chairperson, Founder, Friends of Cancer Research
Light refreshments provided.
The original architects of the personalized medicine paradigm envisioned an era in which clinicians could predict, prevent and treat disease based on an improved understanding of how human biology interacts with external environments. During this session, Ralph Snyderman, M.D., Chancellor Emeritus and James B. Duke Professor of Medicine, Duke University, will moderate a panel discussion to examine our progress on each of these fronts during a wide-ranging conversation with three other leaders in the effort to advance personalized medicine.
MODERATOR | Ralph Snyderman, M.D., Chancellor Emeritus, James B. Duke Professor of Medicine, Duke University
Sean George, Ph.D., CEO, Invitae
Luba Greenwood, J.D., Strategic Business Development and Corporate Ventures, Verily
Keith Stewart, M.B., CH.B., Carlson and Nelson Endowed Director, Center for Individualized Medicine, Mayo Clinic
LEADER | Richard Hamermesh, D.B.A., co-Faculty Chair, Harvard Business School Kraft Precision Medicine Accelerator
Recognizing the need for evidence that underlines the value of the genetic sequencing tests that help make personalized medicine possible, the Personalized Medicine Coalition has commissioned research that examines the clinical and economic benefits of genetic sequencing for non-small cell lung cancer patients and patients with rare and undiagnosed diseases. During this session, researchers involved in those studies will discuss their work with payer representatives and the audience.
MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition
Aris Baras, M.D., Vice President, Regeneron Pharmaceuticals; Head, Regeneron Genetics Center
Kristine Bordenave, M.D., F.A.C.P., Lead Medical Director, Humana
Scott Ramsey, M.D., Ph.D., Member, Fred Hutchinson Cancer Research Center
Sustaining the pace of innovation in personalized medicine will require continued investment in new initiatives, but the financial outlook for the field remains unclear. In that context, this panel of investors will examine whether personalized medicine is at an impasse, an inflection point, or somewhere in between.
MODERATOR | Damian Garde, National Biotech Reporter, STAT News (invited)
Alexis Borisy, Partner, Third Rock Ventures (invited)
Gregory Dorn, M.D., President, Group Head, Hearst Health
Michael Pellini, M.D., Managing Partner, Section 32
SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition